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Antiepileptic drugsTreatment-resistant seizures affect about a third of patients suffering from epilepsy. To fulﬁll the need for new
medications targeting treatment-resistant seizures, a number of rodent models offer the opportunity to assess
a variety of potential treatment approaches. The use of such models, however, has proven to be time-
consuming and labor-intensive. In this study, we performed pharmacological characterization of the allylglycine
(AG) seizuremodel, a simple in vivomodel forwhichwe demonstrated a high level of treatment resistance. (D,L)-
Allylglycine inhibits glutamic acid decarboxylase (GAD) – the key enzyme in γ-aminobutyric acid (GABA) bio-
synthesis – leading to GABA depletion, seizures, and neuronal damage.We performed a side-by-side comparison
of mouse and zebraﬁsh acute AG treatments including biochemical, electrographic, and behavioral assessments.
Interestingly, seizure progression rate and GABA depletion kinetics were comparable in both species. Fivemech-
anistically diverse antiepileptic drugs (AEDs) were used. Three out of the ﬁve AEDs (levetiracetam, phenytoin,
and topiramate) showed only a limited protective effect (mainly mortality delay) at doses close to the TD50
(dose inducing motor impairment in 50% of animals) in mice. The two remaining AEDs (diazepam and sodium
valproate) displayed protective activity against AG-induced seizures. Experiments performed in zebraﬁsh larvae
revealed behavioral AED activity proﬁles highly analogous to those obtained inmice. Having demonstrated cross-
species similarities and limited efﬁcacy of tested AEDs, we propose the use of AG in zebraﬁsh as a convenient and
high-throughput model of treatment-resistant seizures.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Therapy resistance represents a major issue in the management of
epilepsy. Diverse potential mechanistic causes have been proposed
[1–4], and new experimental approaches have been established in
order to discover therapies providing better efﬁcacy [5,6]. Nevertheless,
a clear medical need remains in order to achieve complete seizurescience Group, Biotechnology
Centre (Forskningsparken),
34, +47 950 40178 (mobile);
UCB Biopharma sprl, Avenue de
2 2 386 6499; fax: +32 2 386
uerra), rafal.kaminski@ucb.comcontrol in a substantial population of patients with treatment-
resistant epilepsy [7].
Treatment-resistant epilepsy is deﬁned clinically as a failure of ade-
quate trials of two tolerated, appropriately chosen and used antiepilep-
tic drug schedules (whether as monotherapies or in combination) to
achieve sustained seizure freedom. Such a resistancemight be complete
or partial as the patient experiences a reduction in either seizure fre-
quency or intensity [4]. Similarly, treatment resistance in animalmodels
of epilepsy is deﬁned as the persistence of seizure activity that does
not respond to monotherapy with at least two appropriately chosen
antiepileptic drugs (AEDs). It must be recognized, however, that the dif-
ferentiation between complete responsiveness and partial responsive-
ness may be difﬁcult in animals and depends on seizure protection
endpoints [8].
Preclinical AED discovery has evolved from acute classical seizure
models (chemical and electrical) to more complex designs involving
the induction of spontaneous recurrent seizures and chronicmonitoring
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[9]. These models have allowed for the identiﬁcation of some factors
(molecular and genetic) linked to drug resistance in epilepsy, but they
have limited throughput and are still not commonly used for drug test-
ing purposes. For example, phenytoin-resistant kindled rats [10] and,
more recently, lamotrigine-resistant kindled rats [11]were well charac-
terized as potential models for treatment resistance, but they required
an invasive surgical approach and a laborious selection process. There-
fore, a simpler in vivo model suitable for larger scale early-stage drug
development screening is still needed.
The zebraﬁsh is an increasingly accepted model organism to study
neurological disorders because of its similarity to humans with regard
to neurotransmitter systems and stress axis organization [12]. It com-
bines easy handling and relatively high-throughput screening with the
complexity of a whole vertebrate organism. Within the past decade,
the usefulness of zebraﬁsh in epilepsy research has been validated
through studies involving pharmacologically induced acute seizure
models [13–15] as well as zebraﬁsh models of genetic epileptic
syndromes (Angelman's [16], Lowe's [17], BNFC [18], EAST [19], and
Dravet [20,21]). More recently, some of these zebraﬁsh models have
been applied in high-throughput epilepsy drug discovery (PTZ [22]
and Dravet [20]).
The GABAergic system, one of the main inhibitory neurotransmitter
pathways, has proven to be a valuable target for AEDs. However, the
possible routes of enhancement or modulation include positive alloste-
ric modulation of GABAA receptors (diazepam, DZP) as well as, for ex-
ample, inhibition of GABA reuptake (tiagabine, TGB) [23], synthesis, or
metabolism (valproate, VPA and vigabatrin) [24,25].
Glutamate, in contrast, is part of the principal excitatory pathway
that interacts with both ionotropic receptors which open cation-
permeable channels and G-protein-coupled metabotropic receptors
[26,27]. It is well established that increased glutamate release canwors-
en or prolong seizure activity and plays amajor role in the persistence of
excitotoxicity [28–30]. Glutamate receptors are, therefore, also targeted
byAEDs, e.g., topiramate (TPM) [31] and perampanel [32]. Furthermore,
it has been suggested that convulsions may arise from either an
impairment of GABAergic and/or excessive glutamatergic function
[33–35]. Accordingly, although no consistent correlation was reported
between ictal foci and reduced GABA levels in patients with drug-
refractory seizures, glutamate decarboxylase (GAD, EC 4.1.1.15)
activity was signiﬁcantly decreased in the human cortex [36]. Interest-
ingly, (D,L)-allylglycine (AG, 2-amino-4-pentenoic acid) interferes with
the synthesis of GABA via a mixed-mechanism inhibition of GAD, lead-
ing to decreased GABA levels [37] and increased glutamine concentra-
tions in the brain [38,39], with glutamate levels remaining unchanged
in these studies. As a result, the ratio between inhibitory and excitatory
neurotransmitters was dramatically changed, which could lead to initi-
ation of seizures after in vivo AG exposure. In vitro studies have shown
AG to be a ratherweakGAD inhibitor, although regional variations in ce-
rebral GAD activity following AG administration indicated possible dif-
ferences in entry or metabolism of AG in the brain [40]. Oxidative
deamination of AG resulted in the formation of its metabolite, 2-keto-
4-pentenoic acid, which was shown to be a more potent GAD inhibitor
in mice [37].
Allylglycine has been reported to induce convulsions in rodents [37,
41] and goldﬁsh [42] and to enhance epileptic responses triggered by
photic stimulation in baboons [41]. However, only a few studies were
performed to correlate in vivo convulsive behavior with cerebral
GABA and glutamate levels after AG injection [37–39]. Furthermore,
only a few pharmacological studies in the context of AG-induced sei-
zures have been reported so far. An indirect protective effect was de-
scribed for clobazam as it reversed the AG-induced decrease of
convulsive threshold in baboonswith photosensitive epilepsy [43]. Phe-
nobarbital and VPA elevated the electroconvulsive threshold decreased
by AG in rats [44]. Flunarizine and some AEDs of the ﬁrst generation
(PHT, clonazepam, and primidone) were reported to decrease seizureoccurrence and to delay mortality in rats following intravenous admin-
istration of AG, but active doses were much higher than those inducing
motor impairment in the rotarod test [45,46]. Further pharmacological
characterization should, therefore, be performed to obtain a more de-
tailed proﬁle of treatment responsiveness or resistance in the AG
model in mice. Finally, there are no reports of the potential use of AG
as a model of seizures in zebraﬁsh.
With regard to clinical relevance, AG-mediated GAD inhibition prob-
ably best mimics human neurological conditions that lead to inhibitory
interneuron loss and, subsequently, lowered GAD/GABA levels. One
form of acquired epilepsy resulting from interneuron loss is temporal
lobe epilepsy (TLE) [47,48]. Furthermore, GABA-deﬁcient epileptic syn-
dromes also exist in genetic forms of epilepsy in humans or mice. Some
examples include the following: 1) X-linked lissencephaly with abnor-
mal genitalia, resulting from ARX (Aristaless Related Homeobox) muta-
tions, with patients often displaying intractable epilepsy [49–51];
2) DLX1 (Distal-less Homeobox 1) mutant mice [52]; 3) loss of GABA-
positive cortical interneurons in the uPAR (Urokinase Plasminogen
Activator Receptor) knockout mouse [53,54]; and 4) dysregulated
GABA-mediated synaptic inhibition as a result of disorganized hippo-
campal interneurons in Lis1 (Lissencephaly 1) mutant mice [55–58].
The goals of this study were to evaluate the effects of an acute ad-
ministration of AG in mice and zebraﬁsh larvae and to compare the
behavioral, electrographic, and biochemical changes as well as the
responseswith pharmacological treatmentwithﬁvemechanistically di-
verse AEDs in both species. If cross-species similarities in terms of sei-
zure behavior and pharmacology are conﬁrmed, we may conclude
that the use of AG in zebraﬁsh could allow high-throughput screening
for novel small molecules targeting treatment-resistant seizures.
2. Material and methods
2.1. Validation of the AG seizure model in mice
2.1.1. Animals
Male NMRI mice (Charles River, France) weighing 20–32 g were
used in all experiments. They were maintained on a 12/12-hour light/
dark cycle with lights on at 06:00 AM and had free access to food and
drinking water. The temperature in the husbandry facility was main-
tained at 20–21 °C and the humidity at about 40%. For each experiment,
the mice were housed in groups of 8–10 per cage and habituated for at
least 1 h in the experimental room. All procedures were carried out ac-
cording to the Declaration of Helsinki and conducted according to the
guidelines of the European Community Council directive 86/609/EEC.
Local Ethics Committees approved all performed experiments.
2.1.2. Drug treatments
(D,L)-Allylglycine (AG; Sigma), levetiracetam (LEV; UCB Pharma,
Belgium), and sodium valproate (VPA; Sigma) were dissolved in 0.9%
saline. Diazepam (DZP; Apin Chemicals), phenytoin (PHT; Fluka), and
topiramate (TPM; UCB Pharma, Belgium)were suspended in 0.9% saline
containing 0.1% Tween 80. The injection volume was 10 ml/kg body
weight. All AEDs were administered through the intraperitoneal (i.p.)
route simultaneously or 90 min after AG injection. Antiepileptic drug
pretreatment time points were chosen based on preliminary studies
matching the onset of AG-induced seizures with the well-established
pharmacokinetic proﬁle of these AEDs in mice [59]. Control groups re-
ceived the respective vehicle solution. Additionally, mortality was
assessed in each group at 4 h and 24 h post-AG injection.
2.1.3. AG dose–response curve
Different groups of 10 mice were injected i.p. with increasing doses
of AG ranging from 100 to 300 mg/kg and were placed in individual
cages for a period of 3 h of observation. Themice ﬁrst exhibited tremors
and, sometimes, Straub tail, i.e., tail erected in a nearly vertical position,
followed by myoclonus during the ﬁrst hour postinjection. Later on,
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ﬁcations [61]: stage 3— repetitive forelimbs movements and head bob-
bing, stage 4 — clonus with rearing, and stage 5 — continuous rearing
and falling.
2.1.4. Electroencephalographic (EEG) recordings
Each mouse was anesthetized with an i.p. injection of ketamine
(Imalgen, 50 mg/kg) and medetomidine (Domitor, 1 mg/kg). Analgesia
was provided with subcutaneous administration of 100 μl of lidocaine
(lignocaine, 2% as HCl salt) at the site of electrode implantation. The
mouse was then secured in a stereotaxic frame, a skin incision was
made, and small holes were drilled through the skull. Platinum elec-
trode assembly was secured in place with dental cement (Caulk
Dentsply, Milford, DE, USA). Electrodes (Supplementary Fig. 1B) were
implanted into the right hippocampal CA1 area (bregma:−1.94 mm,
lateral: 1.0 mm, and depth:−1.25 mm), and surface electrodes were
placed on the dura matter at the left frontal cortex level (bregma:
+1mm and lateral: +2mm) and at the occipital cortex level (bregma:
±3 mm and lateral: ±4 mm). A recovery period of 2 weeks was
allowed before EEG recordings were performed in freely moving mice
during daylight time (between 8 AM and 12 AM). Mice were injected
i.p. with 275 mg/kg of AG and were placed in individual EEG cages
for monitoring. The illustration of the video-EEG recording setup is
shown in Supplementary Fig. 1A. Electroencephalographic signals
were recorded in a frequency band of 1–35 Hz (Hertz) with 5000-gain
factor (Grass software, Gamma 4.7).
2.1.5. Data analysis and statistics
Proportions of seizures and mortality were expressed as number of
responding mice (n) versus total number (N) in each group of animals,
and comparison between the vehicle-treated group and the drug-
treated group was performed for each drug and dose using Fisher's
exact probability test. For each tested drug, median as well as 25% and
75% percentiles for time to recurrent seizure onset were calculated for
the tested dose, and statistical comparison versus the vehicle control
group was obtained with a one-way ANOVA test followed by Dunn's
comparison (GraphPad Prism 5, San Diego, CA).
2.2. Validation of the AG seizure model in zebraﬁsh larvae
2.2.1. Animals
Fertilized zebraﬁsh eggs of the wild-type AB strain obtained by nat-
ural spawning were maintained at 28.5 °C under constant light condi-
tions in embryo medium (1.5-mM HEPES, pH 7.6, 17.4-mM NaCl,
0.21-mM KCl, 0.12-mM MgSO4, and 0.18-mM Ca(NO3)2). Seven-day-
old larvae were used in all experiments. All the experiments were con-
ducted in accordance with the animal experimentation regulations of
KU Leuven (ECD P101/2010).
2.2.2. Drug treatments
Allylglycine, levetiracetam, and topiramate were purchased from
Sigma; other AEDs used in this study were the following: DZP (Roche),
VPA (Sanoﬁ-Aventis), and PHT (Acros). All compounds were dissolved
in dimethylsulfoxide (DMSO) and were diluted in embryo medium to
achieve a ﬁnal DMSO concentration of 1% weight/volume (w/v).
Embryo medium prepared with DMSO to a ﬁnal concentration of
1% w/v served as vehicle control (VHC).
2.2.3. Locomotor tracking
The larvae were placed individually in the wells of a 96-well plate;
ten larvae were used per treatment group. Allylglycine was used in
the concentration range of 30–300 mM; AEDs were tested at their re-
spective maximal tolerated concentrations (MTCs): VPA (0.5 mM),
TPM (200 μM), DZP (16 μM), LEV (10 mM), and PHT (100 μM); all
were applied simultaneouslywith AG. Tolerability testswere performed
as described previously [15]; brieﬂy, touch response and postureabnormalities were scored after overnight exposure, and a concentra-
tion was considered unacceptable if more than 2 larvae out of 12
showed no touch response or died. As it is currently not possible to de-
termine the amount of drug taken up in zebraﬁsh larvae, we tested lar-
val behavior both after a short (1-hour) and a long (overnight, 16-hour)
exposure to determine whether there would be differences in uptake
and potential toxicities upon longer exposure [15]. Behavioral analysis
started within 5 min after AG application in the dark chamber of an au-
tomated tracking device (ZebraBox™ apparatus; Viewpoint, Lyon,
France). Tracking time was 6 h or 8 h. This extended monitoring
period was carried out because for any given larva treated with 50-mM
or 70-mM AG, peak locomotor activity (total movement) was observed
anywhere between 2 h and 7 h. Each larva only showed one activity
peak per 8-hour tracking period, and the time at which peak locomotor
activity (per larva) could be observed during this 8-hour period was un-
predictable. Thus, for consistency and comparison purposes, we chose
the long tracking time of 8 h for all concentrations tested. This was also
to determine whether any of the tested AEDs could prevent death or at
least extend the period to death. At 300-mMAG, all larvae displayed con-
vulsive behavior within 1 1/2 to 2 h after administration. Since this time
window was narrower and more predictive of when larvae would
have seizures, we decided to use AG at 300-mM for all subsequent
experiments.
Locomotor activity was then quantiﬁed using ZebraLab™ software
(Viewpoint, Lyon, France). Total movement or activity was expressed
in “actinteg” units. The actinteg value of the ZebraLab™ software is de-
ﬁned as the sum of all image pixel changes detected during the time
windowdeﬁned for the experiment.WhenAEDs signiﬁcantly decreased
total AG-induced movement at their MTCs, a lower (1/2 MTC) concen-
trationwas tested aswell. The lower effective concentrationswere cho-
sen for electrographic recordings in the case of VPA and DZP because of
a prolonged survival time with AG at those concentrations compared
with the higher ones.
2.2.4. Electrographic recordings
Each larva was incubated with 300-mM AG in combination with
AED or VHC for 2 h at room temperature (20 °C). A larva was then
embedded in 2% low-melting-point agarose; a glass electrode ﬁlled
with artiﬁcial cerebrospinal ﬂuid (ACSF) composed of 124-mM NaCl,
2-mM KCl, 2-mM MgSO4, 2-mM CaCl2, 1.25-mM KH2PO4, 26-mM
NaHCO3, and 10-mM glucose (resistance: 1–5 MΩ) was placed into
the optic tectum; and recordings were performed in current clamp
mode, low-pass ﬁltered at 1 kHz, high-pass ﬁltered 0.1 Hz, and digital
gain 10 at sampling intervals of 10 μs (MultiClamp 700B Ampliﬁer,
Digidata 1440A Digitizer, both Axon instruments, USA). The recordings
started each timeexactly 5min after the removal of the larva from treat-
ment incubation solution and were continued for 10 min.
Importantly, although larvae were embedded in low-melting point
agarose, they were kept bathed in ACSF (see above) for the duration
of the recordings, which were carried out only within the ﬁrst 15 min
postremoval from AG solution. These steps were taken so as to prevent
potential artifacts. Moreover, spiking activities in controls were ob-
served occasionally, but the patterns were considerably different from
those observed for AG-treated larvae. These were characterized by sin-
gle spikes of very short duration and have been described previously by
Baraban and colleagues as bursts of synchronized activity [62].
Recordings from at least 10 larvae were taken per experimental
condition. Importantly, in order to avoid any misinterpretation of
the potential antiseizure effects of AED treatments, only the days of ex-
perimentwhere all AG-treated zebraﬁsh larvae displayed recurrent sei-
zures were taken into account. Spontaneous 10-min duration gap-free
recordings were analyzed for all larvae (n = 72). A threshold for in-
clusion of AG-induced events was set at three times the background
noise and 100-ms duration; all events exceeding these thresholds
were analyzed. Electrophysiological recordings were analyzed post
hoc in a single-blinded way using Clampﬁt 10.2 software (Molecular
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for local ﬁeld potential recordings in zebraﬁsh.2.2.5. GABA/glutamate determination
Larvaewere subjected to 300-mMAG for up to 120min. After the se-
lected time, larvae were washed with ice-cold phosphate buffered sa-
line (PBS), and their heads (6 per tube) were homogenized on ice for
1 min in 100 μl 0.1-M sodium acetate buffer pH 6.8. Homogenates
were centrifuged at 15,000 g for 15 min at 4 °C. Supernatants (70 μl)
were transferred to a clean tube and stored at−70 °C.
The supernatant were diluted 50 times for the determination of
GABA content by reverse-phase isocratic microbore LC with ampero-
metric detection as described above. For glutamate analysis, the super-
natant was diluted 5 times. We used a reverse-phase narrow bore assay
with gradient elution and ﬂuorescence detection. Fifteen microliters of
the diluted supernatant were automatically derivatized with OPA in
the presence of β-mercaptoethanol and also at 4 °C by a cooled (832
temperature regulator, Gilson, France) 231XL sampling injector (Gilson,
France). This one-step precolumn derivatization preceded the injection
of 10 μl of the sample on a C18 narrow bore column (5-μmparticle size,
250 × 2mm, Capcell PakMG®, Shiseido). The samples were eluted by a
Dionex P680 HPLC pump with the previously described mobile phases
and gradient program [63]. Detection was performed with a RF 10A
XL ﬂuorescence detector (Shimadzu).Fig. 1. (A) Seizure incidence in allylglycine (AG)-treatedNMRImice. Animals (N=10/dose)we
of convulsions. Seizureswere scored according to Racine's scale [60,61]. Open bars—myoclonu
mortality 3 h post-AG. Statistical signiﬁcance compared with vehicle-treatedmice (Fisher's exa
onset after injection of 275-mg/kg AG. Dots represent time to onset, and lines representmedian
3 h post-AG.2.2.6. Statistical analysis
The effects of AEDs on AG-induced locomotion and changes in neu-
rotransmitter levels were estimated using a one-way ANOVA followed
by Dunnett's multiple comparison test. The effects of AEDs on
electrographic activity were analyzed using the Student two-tailed un-
paired t-test or the Mann–Whitney rank sum test for data that failed
the normality test, as appropriate. The area of WISH staining in AG
and AED-treated groups was compared with the one of VHC control in
one-way ANOVA with subsequent Bonferroni posttest (GraphPad
Prism 5, San Diego, CA).3. Results
3.1. AG dose–response proﬁle in mice
A clear progression in the number of mice exhibiting convulsions
was observed with increasing doses of AG. The proportion of mice
showing recurrent clonic seizures (stages 3–5 on modiﬁed Racine's
scale [60,61]) increased from 60% at a dose of 225 mg/kg to 100% at
the maximal tested dose of 300 mg/kg. However, the latter dose was
associated with high mortality (Fig. 1A). We selected the dose of
275 mg/kg for further investigation and AED testing. This dose induced
recurrent seizures in about 90% of mice with limited mortality during
the 3 h of observation. At that dose, the occurrence of myoclonicre injected intraperitoneally using increasingdoses of AGandobserved for 3 h for incidence
s; black bars— recurrent clonic convulsions; hatched bars— tonic convulsions; gray bars—
ct probability test) marked as * (p b 0.05), ** (p b 0.01), *** (p b 0.001). (B) Time to seizure
s. M—myoclonus; C— recurrent clonic convulsions; T— tonic convulsions; D—mortality
Fig. 2. Effects of allylglycine (AG) on locomotor activity of zebraﬁsh larvae. Time-course of
locomotor activity (actinteg units/min) of individual larvae shown in different colors;
curves of 10–12 larvae from one treatment group plotted together, representative
experiments shown. (A) VHC, (B) 50-mM AG, (C) 100-mM AG, (D) 200-mM AG, and
(E) 300-mM AG. Arrows indicate the time points when 50% of the ﬁsh in the group died.
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followed by clonic convulsions, ﬁrst in the forelimbs (stage 3) then
evolving to clonus in all limbs with loss of balance (stages 4–5) [60]
(Fig. 1B). Tonic convulsions were observed in about 30% of mice and
were usually associated with mortality.
The mouse pharmacokinetic (PK) proﬁle of AG in general matched
the one described before in a previous study [38] (data not shown).
3.2. Behavioral response of zebraﬁsh larvae to AG
Similar to mice, zebraﬁsh larvae at 7 days postfertilization (dpf)
displayed increased locomotor activity in response to various concen-
trations of AG. Behavioral manifestations followed the sequence and
pattern (stages 1–3) described previously in zebraﬁsh of this develop-
mental stage [13], namely, increased swimming activity, followed by
whole body convulsions and a subsequent loss of posture.
Pilot experiments showed that the locomotor hyperactivity of AG-
treated larvae developed relatively slowly when compared with other
proconvulsants (e.g., 20-mM pentylenetetrazol, PTZ) [13,15]. Allylglycine
at 30mMdid not induce changes in locomotor activity,with treated lar-
vae exhibiting an identical level of total movement to that of VHC-
treated controls within 6 h of tracking (data not shown). A range be-
tween 50-mM AG and 100-mM AG increased the overall motility of
the larvae, though bursts of movement for individual larvae occurred
asynchronously throughout the observation time. Locomotor hyperac-
tivity of individual larvae peaked between 2.5 h and 8 h from the start
of tracking. Exposure to this concentration rangewas relativelywell tol-
erated, so that even at 100mM, 50 to 80% of larvaewere still alive at the
end of each tracking session (Fig. 2 and data not shown).
At a higher concentration range (200- to 300-mM AG), latency time
to increased locomotor activity was signiﬁcantly shortened. In contrast
to the lower concentrations of AG tested, peaks in locomotor activity be-
came more synchronized although their amplitudes followed a down-
ward trend. This period of increased motility was followed by an
irreversible decline in locomotion and subsequent death of all larvae
from 3 h onward of an 8-hour total observation period (Fig. 2).
Comparison of results between mice and zebraﬁsh showed that
seizure onset occurred in both species after a similar latency time. This
latency period was described previously in mice (44–240 min) and in
rats (120–150 min) by Horton and Meldrum [41] and Alberici et al.
[64], respectively. A wide variation in seizure onset between test
animals was also reported by these authors. In AG-injected mice
(i.p., 115-mg/kg AG, dose inducing convulsions in 50% ofmice), seizures
were described to begin after 2–4 h, recur for 1–2 h, and lead to death in
2 out of 5 animals having convulsions. We observed a comparable con-
vulsive proﬁle inmice but were able to use a higher dose of AG (dose in-
ducing 90% of recurrent seizures) for testing of AEDs. In zebraﬁsh,
convulsive behaviors were observed for the majority of larvae within
1.5 to 2 h of bathing in 300-mM AG. Similar to rodents, increasing the
dose shortened the latency to death more than the latency to seizures
[41].
3.3. Electrographic brain activity in AG-treated mice
Electroencephalographic activity recorded in mice following acute
AG injection (275 mg/kg, i.p.) showed typical spike–wave discharges
starting in the hippocampus from 2 h postinjection. Ictal activity was
observed during each episode of clonic convulsions (e.g., t = 136 and
t = 187 min postinjection; Fig. 3), which appeared to spread from the
hippocampus to the cortex. Suppression of EEG amplitude with very
few isolated spikes was also observed between such seizure episodes
(e.g., t = 162min; Fig. 3). This pattern of evolution of electrographic ac-
tivity is comparable with that described for other chemoconvulsants,
e.g., kainate or 4-aminopyridine, but ictal events appear much later
after administration of AG [65,66].3.4. Electrographic brain activity in AG-treated zebraﬁsh larvae
To conﬁrm that application of 300-mM AG resulted in abnormal
brain activity in zebraﬁsh, we performed local ﬁeld potential recordings
from 7-dpf larval optic tecta. Epileptiform paroxysmal events consisted
of polyspiking discharges (PDs) with amplitudes equal to or exceeding
threefold baseline and were detected starting from the range of 90–
120min of AG exposure onwards. Such recurrent, induced epileptiform
events occurred in the vast majority of larvae at a mean frequency of
16.4± 3.7 events/10-min recording. Themean duration of epileptiform
events was 671 ± 23 ms (n = 14 ﬁsh, 230 events analyzed, data not
shown).3.5. Neurotransmitter levels in AG-treated zebraﬁsh
The concentration of GABA remained at the level of untreated larvae
until 20 min following 300-mM AG exposure. A slight downward trend
in GABA levels was ﬁrst observed at 40 min and became signiﬁcantly
lower (one-way ANOVA) than at time point zero starting from 60 min
onwards (Fig. 4A). The levels of glutamate did not signiﬁcantly change
at the time points tested. The GABA/glutamate ratio dropped
Fig. 3. Effects of allylglycine (AG) on electrographic activity inmouse hippocampus. Continuous electroencephalographic (EEG) recordings were performed after intraperitoneal injection
of 275 mg/kg of AG. CTX — left frontal cortical electrode; HPC — hippocampal electrode.
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(Fig. 4B), which matches with the time frame of epileptiform activity
occurrence in the tectal ﬁeld recordings.
Despite different administration routes used for AG (i.p. injection in
mice versus bath exposure in zebraﬁsh larvae), the time-course of GABAdepletion in zebraﬁsh matched with the residual activity of GAD
estimated in mice previously by Horton and Meldrum [41] (at the
dose of 200-mg/kg AG, in BALB/C mice, GAD activity dropped by about
35% of the initial values at 90 min post-AG injection followed by
seizures in the span of 95–180 min post-AG dose).
Fig. 4. Neurotransmitter levels in zebraﬁsh. Zebraﬁsh exposed to 300-mM AG for a designated time were sacriﬁced, their heads were isolated, and the level of neurotransmitters was
determined. (A) Levels of GABA (closed circles) and glutamate (open squares) in zebraﬁsh head homogenates; (B) GABA/glutamate ratio. * p b 0.05 and ***p b 0.001 versus basal concen-
tration (one-way ANOVA). Error bars show SEM.
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We tested ﬁvemechanistically diverse AEDs thatwere administered
at two different time points in relation to AG injection. Because of the
abovementioned long latency to seizure onset after AG injection, we
administered these compounds either simultaneously with AG or
90 min later.Table 1
Effects of AEDs on the proportion of AG-treated mice with delay in seizure occurrence and mo
Statistical comparison versus vehicle control (dose 0) for time to event was performed with
Signiﬁcant difference for proportion of responding mice between the treated group and the cont
A dose of 275 mg/kg AG was used.
Drug Doses
(mg/kg)
Time
post-AG inj.
(min)
Myoclonus
n/N
Time to
myoclonus
(min)
Recurrent
clonus
n/N
VPA 0 0 9/10 109 (94–163) 7/10
166 10/10 175 (121–193) 6/10
299 8/10 183 (169–226)* 4/10
0 90 8/8 85 (78–101) 8/8
166 8/8 94 (78–140) 7/8
299 8/8 88 (78–95) 4/8#
LEV 0 0 17/18 100 (94–112) 17/18
306 8/8 164 (142–184)* 8/8
544 16/18 145 (112–155) 15/18
953 17/18 149 (112–184)* 12/18#
0 90 8/8 96 (95–101) 8/8
306 8/8 93 (80–102) 8/8
544 8/8 108 (95–139) 8/8
953 8/8 109 (81–115) 8/8
PHT 0 0 16/18 104 (84–145) 14/18
25 5/8 179 (138–240) 4/8
45 5/8 158 (123–240) 4/8
81 18/18 103 (83–146) 15/18
0 90 8/8 99 (95–119) 8/8
25 8/8 98 (93–106) 8/8
45 8/8 103 (94–114) 8/8
81 8/8 106 (87–112) 8/8
TPM 0 0 8/8 107 (87–150) 6/8
34 8/8 124 (116–149) 4/8
109 7/8 149 (101–224) 4/8
340 6/8 173 (110–236) 4/8
0 90 8/8 112 (103–124) 8/8
34 8/8 114 (95–157) 5/8
109 7/8 130 (115–158) 6/8
340 7/8 105 (93–178) 5/8
DZP 0 0 8/8 90 (74–178) 6/8
1.6 8/8 124 (102–177) 6/8
2.9 6/8 192 (144–235) 2/8
5.1 3/8# 240 (198–240)** 1/8#
0 90 8/8 102 (86–116) 6/8
1.6 7/8 159 (77–213) 1/8#
2.9 4/8# 165 (79–240) 1/8#
5.1 2/8## 240 (128–240) 0/8##Valproate dose-dependently decreased the proportion of mice
exhibiting recurrent seizures (Table 1); this effect was statistically
signiﬁcant at 299 mg/kg when VPA was injected 90 min post-AG
(275 mg/kg), and the time to seizure onset was signiﬁcantly increased
(Table 1). Valproate also delayed onset but did not protect against mor-
tality with a signiﬁcant effect observed at 166 mg/kg when adminis-
tered 90 min post-AG (Table 1).rtality. Seizures were scored according to Racine's scale with minor modiﬁcations [60,61].
one-way ANOVA followed by Dunn's multiple comparison test: *p b 0.05 and **p b 0.01.
rol group was calculated with Fisher's exact test and marked as #(p b 0.05) or ##(p b 0.01).
Time to recurrent
clonus (min)
Mortality at 4 h
post-AG inj.
n/N
Time to mortality
(min)
Mortality at 24 h
post-AG inj.
n/N
150 (134–240) 8/10 177 (148–238) 8/10
221 (184–240) 4/10 240 (199–240) 6/10
240 (227–240)* 0/10## 240 (240–240) ** 6/10
104 (101–108) 8/8 128 (116–140) 8/8
166 (152–190)* 1/8## 240 (240–240)** 8/8
223 (155–240)** 1/8## 240 (240–240)** 7/8
129 (120–156) 15/18 174 (149–227) 18/18
206 (197–226)* 1/8## 240 (172–240) 5/8
167 (144–210) 9/18# 237 (213–240)* 16/18
216 (165–240)** 0/18## 240 (240–240)** 16/18
117 (106–144) 8/8 143 (132–163) 8/8
123 (114–134) 8/8 140 (130–172) 8/8
133 (111–150) 7/8 183 (117–194) 8/8
132 (124–170) 4/8# 237 (168–240) 7/8
164 (123–187) 15/18 171 (147–223) 18/18
216 (151–240) 0/8## 240 (240–240)** 5/8#
222 (154–240) 0/8## 240 (240–240)** 2/8##
188 (145–216) 2/18## 240 (240–240)** 12/18
125 (106–156) 7/8 167 (136–214) 8/8
127 (103–153) 3/8 240 (196–240) 8/8
136 (128–170) 2/8# 240 (238–240) ** 7/8
156 (116–171) 4/8 238 (225–240) 6/8
156 (130–227) 3/8 240 (167–240) 6/8
226 (181–240) 2/8 240 (240–240) 8/8
222 (164–240) 3/8 240 (183–240) 4/8
236 (176–240) 0/8 240 (240–240) 1/8#
155 (139–160) 7/8 227 (203–237) 7/8
169 (149–240) 4/8 225 (175–240) 6/8
187 (157–228) 0/8## 240 (240–240)** 2/8#
189 (159–240) 0/8## 240 (240–240)** 0/8##
137 (121–219) 6/8 148 (126–220) 6/8
165 (156–227) 3/8 240 (216–240) 8/8
240 (227–240)* 0/8## 240 (240–240) ** 6/8
240 (240–240)** 0/8## 240 (240–240) ** 5/8
127 (103–214) 5/8 211 (145–240) 7/8
240 (240–240) 1/8 240 (240–240) 4/8
240 (240–240)* 0/8# 240 (240–240)* 2/8#
240 (240–240)** 0/8# 240 (240–240)* 0/8##
60 K. Leclercq et al. / Epilepsy & Behavior 45 (2015) 53–63Levetiracetam and phenytoin reduced the proportion of mice
exhibiting recurrent seizures when administered simultaneously with
AG (Table 1) but were completely ineffective when administered at
90 min post-AG. These two AEDs are usually tested in acute models at
60 and 120 min, respectively [59], for optimal efﬁcacy. Levetiracetam
was also able to prolong the latency time to seizure incidence
(Table 1). Phenytoin and, to a lower extent, LEV delayed the occurrence
ofmortality, with a decrease inmortality still observed 24 h after AG but
only at 306 mg/kg for LEV (Table 1). The lower efﬁcacy of PHT at
81 mg/kg, which is likely due to decreased tolerability at this high
dose, is worth noting.
In contrast, TPM did not show a signiﬁcant effect against seizure in-
cidence or time to onset (Table 1) but delayed mortality with maximal
efﬁcacy when administered 90 min post-AG. The mortality was dose-
dependently decreased with a maximal effect observed when TPM
was administered 90 min post-AG (Table 1).
In our hands, the most efﬁcacious AED was DZP, which completely
abolished seizure occurrence at the highest tested dose (5.1 mg/kg)
when administered 90 min post-AG (Table 1). The lower doses
(1.6 and 2.9 mg/kg) signiﬁcantly decreased clonic seizure incidence
and also signiﬁcantly increased the time to seizure onset. Diazepam sig-
niﬁcantly delayed the 4-hour mortality incidence in both regimens of
administration (Table 1) and signiﬁcantly decreased the 24-hour mor-
tality when administered 90 min post-AG. It is worth noting that the
doses used in mice in the case of TPM and PHT were close to their
TD50 values (doses inducing motor impairment in 50% of naïve mice)
estimated in the rotarod test (data not shown). Reported TD50 doses
in the rotarod test are 398–465 mg/kg for VPA, 41–70 mg/kg for PHT,
N500mg/kg for LEV, 318–401mg/kg for TPM, and 6.8mg/kg for DZP, re-
spectively [59,67].
Overall, efﬁcacy of AEDs was rather limited in our experimental
setup. In themouse assays, no complete seizure suppression at the cho-
sen doses was achieved, and the animals were only protected against
mortality at doses close to sedative ones, i.e., PHT at 45mg/kg, diazepam
at 2.9 mg/kg, and TPM at 109 mg/kg.
3.7. Effects of AEDs on AG-induced behavioral changes and electrographic
seizures in zebraﬁsh
In experimentswherein 300-mMAGwas coadministeredwith AEDs
at their respectiveMTCs, VPA andDZP decreased larval locomotor activ-
ity levels signiﬁcantly (Fig. 5A). Topiramate also showed partial sup-
pression of larval movement, while LEV and PHT showed no activity.
Additional experiments showed that VPA and DZP were also active atFig. 5. Effects of AEDs on locomotor and electrographic activities of AG-treated zebraﬁsh larvae. (
totalmovement during 8 h shown as percentage of the AGgroup; AEDs at theirMTCs, readings o
ber of ﬁsh per group indicated above the column; treatment groups with signiﬁcantly decreased
and *** (p b 0.05, p b 0.01, and p b 0.001, respectively). Occurrence (B) and cumulative duration
bination with 5 different AEDs. Mean number of epileptiform events after coincubation with 30
(n = 14, 13, 10, 11, 13, and 11 larvae, respectively). Bars represent SEM; Student's unpaired t-ta lower concentration (1/2 MTC; data not shown), which was chosen
for electrographic recordings due to prolonged survival time. The effect
of TPM was signiﬁcant only at MTC and did not increase further at a
higher concentration (data not shown).
In order to conﬁrm that the larval locomotor response to AEDs
corresponded to an effect on seizure activity, the occurrence of epilepti-
form discharges was then examined in larvae coincubated with AEDs
and 300mMAG for 2 h. Application of VHCwas used as a negative con-
trol. Coapplication of 300-mM AG and DZP (8 μM, n = 10 ﬁsh) or VPA
(250 μM; n = 13 ﬁsh), PHT (100 μM; n = 13 ﬁsh), and TPM (200 μM;
n = 11 ﬁsh) decreased the occurrence of epileptic events compared
with 300-mM AG incubated with vehicle (Fig. 5B; AG + VHC: 16.4 ±
3.7 versus AG + VPA: 2 ± 0.9, AG + DZP: 1.6 ± 1.5,, AG + PHT:
8.7 ± 4.4 and AG + TPM: 4.5 ± 1.7 events/10-min recording; p =
0.0002, p = 0.0002, p = 0.0357 and p = 0.0081, respectively). Only
LEV showed no signiﬁcant effect on the occurrence of epileptiform
events (Fig. 5B, LEV; 10 mM, n = 11 ﬁsh, AG + VHC: 16.4 ± 3.7 versus
LEV: 10.5±2.9 events/10-min recording, p=0.2315). Similarly, the cu-
mulative duration of epileptiform events, i.e., the fraction of time spent
in epileptic activity,was signiﬁcantly decreased for all treatments except
LEV (Fig. 5C; AG + VHC: 11,031 ± 2799 versus AG + VPA: 407 ± 185,
AG + DZP: 1555 ± 1505, AG + LEV: 6292 ± 1803, AG + PHT:
3140 ± 1517, and AG + TPM: 1577 ± 634 ms/10-min recording,
p b 0.0001, p=0.0007, p=0.1947, p=0.0048, andp=0.0052, respec-
tively). Representative recordings of electrographic activities in seizure-
free larvae are shown as examples for DZP (Fig. 6B) and VPA (Fig. 6C).
Importantly, none of the treatments afforded complete seizure protec-
tion in the given time frame — i.e., neither prevention nor delay in
mortality of zebraﬁsh larvae was achieved (data not shown).
4. Discussion
In general, AED ability (or inability) to suppress convulsions in mice
correlated well with the data obtained for the larval locomotor re-
sponse, even though AEDswere evaluated at their TD50 or MTC, respec-
tively. In summary, VPA and DZP were active in both species with TPM,
PHT, and LEV showing limited to no protection against seizures. More
speciﬁcally, TPM showed partial protection in the locomotor and
electrographic assays in zebraﬁsh but not in mice; the activity of PHT
could only be observed in the electrographic assay in zebraﬁsh, and
LEV increased the latency time to seizures solely in mice (Table 1).
These ﬁndings are in line with the clinical deﬁnition of drug-resistant
epilepsy described as the failure of at least two medications to exhibit
full control of seizures, i.e., seizure freedom [68].A) Recorded locomotor activity of larvae treated with 300-mMAG coincubated with AEDs;
f duplicated experiments normalized andpooled together; error bars show SEM; total num-
locomotor activity compared with that with AG alone (one-way ANOVA) are marked *, **,
(C) of AG-induced epileptiform events in larvae treated with 300-mM AG only or in com-
0-mM AG and VHC, 250-μM VPA, 8-μM DZP, 10-mM LEV, 100-μM PHT, and 200-μM TPM;
est or Mann–Whitney test was used for data that failed the normality test, as appropriate.
Fig. 6. Representative electrographic recordings of 7-dpf larvae incubated with 300-mM AG displaying paroxysmal polyspiking discharges (PDs). (A–C) Top trace represents a typical 10
min-epileptiform pattern as seen in gap-free recordings. Bottom traces show high-resolution magniﬁcations of the top ones. (A) AG in combination with VHC; (B, C) after coincubation
with 300-mM AG and (B) 8-μM DZP or (C) 250-μM VPA. The scales for B and C are the same.
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over adults for drug screening, the potential drawbacks and limitations
must also be taken into consideration. For example, incompletely devel-
oped brain regionsmay limit the aspects of a neurological disorder that
can be studied. Moreover, the larval zebraﬁsh blood–brain barrier is still
largely permeable until 10 dpf. Therefore, proper assessment of drug
uptake into the brain from the circulation and subsequent extrapolation
of appropriate dosage and uptake in mammals are currently not possi-
ble. In addition, some compounds or drugs have proven insoluble in
water (our own observations), thus once again preventing quantiﬁca-
tion of drug uptake and possibly leading to false negatives. In the latter
instance, wewere able to circumvent this solubility problemby improv-
ing the low bioactivity of a compound through microinjection into the
blood circulation after solubilization in 50% DMSO. Surprisingly,
zebraﬁsh embryos were able to survive such high concentrations of
DMSO solvent quite well [69].
Glutamic acid decarboxylase is a rate-limiting enzyme in the GABA
synthesis pathway; it acts by metabolizing glutamate into GABA, thus
directly inﬂuencingGABA concentration. Allylglycine-mediatedGAD in-
hibition could, in part, be due to its metabolite 2-keto-4-pentenoic acid,
which is amore potent blocker of cerebral GAD activity than AG [37,70].
Furthermore, a fewmodels of focal epilepsy are also based on impaired
GABAergic activity, such as hyperbaric oxygen or glutaric acidemia [71,
72]. Similarly, a compound restoring cerebral GABA concentration
(gabaculine) [71] is not sufﬁcient per se to protect against seizure occur-
rence, suggesting that other pathways could also be involved. Thus,
such a screening model will likely be capable of identifying compounds
with different mechanisms of action. According to the data from pa-
tients with epilepsy, GAD activity is decreased in the cortex [36], and
upregulation of GAD isoforms (GAD65 and GAD67) has been described
in the remainingGABAergic neurons in amodel of temporal lobe epilep-
sy [73]. Moreover, GAD autoantibodies have been detected in patients
with treatment-refractory epilepsy [74]. These ﬁndings, therefore,
support the usefulness of animal models modulating GAD activity for
preclinical work in the context of epilepsy.
The mechanism of action of AG, namely, impairment of GABA bio-
synthesis through GAD inhibition, presumably suggests a particular
pharmacological proﬁle of this model. Reduced GABA concentrationsin the brain have been shown to induce convulsions and are associated
with neuronal damage [75]. The imbalance between excitatory and in-
hibitory pathways has been associated with status epilepticus therapy-
resistant seizures [76]. Indeed, classical preclinical seizure screening
models typically target GABAA receptors (e.g., PTZ, bicuculline, and
picrotoxin), but no model currently used widely inhibits GABA biosyn-
thesis. Comparing the pharmacological proﬁles of classical models
(Table 2) with the proﬁle of AG, we see not only a partial overlap but
also unique seizure responsiveness/resistance combinations in each
case.
Other potential perspectives of the AGmodel are based on theobser-
vations that at subconvulsive doses, AG produces an anxiety-like state
and increases vulnerability to panic attacks in animals and humans,
suggesting the added involvement of the serotoninergic system [81].
Several othermodulatory actions on the GABA pathwaywere described
and associated with behavioral manifestations. For example, the
disruption of GABAergic inhibition by a reverse GABAA receptor agonist
(FG-7142) elicited c-fos expression changes in the orexin neuron hypo-
thalamic network involved in stress and panic [82]. An important role
for the GABAergic system has also been reported in the context of hallu-
cinations [83]. Altogether, these mechanisms may possibly lead to the
development of a multiindication drug discovery assay.5. Conclusions
In the course of this study, we have conﬁrmed the biochemical and
encephalographic (EEG) changes induced by AG treatment in mice.
We also report for the ﬁrst time the use of AG for the induction and
monitoring of acute seizures in zebraﬁsh.Moreover, we assessed the ef-
ﬁcacy and potency of ﬁve ﬁrst-line AEDs against AG-induced convul-
sions. Protective effects were observed at relatively high doses only for
two out of ﬁve AEDs. Given that more than half of AEDs showed partial
to no seizure protection, the AG seizure model illustrates treatment re-
sistance to certain AEDswith speciﬁcmodes of action and is in linewith
the ILAE deﬁnition of therapy resistance in patients with epilepsy. Final-
ly, having demonstrated a high degree of cross-species similarities for
this acute AG seizure model, we propose the use of zebraﬁsh for the
Table 2
Efﬁcacy of some AEDs in acute seizure tests involving the GABAergic system.
Treatment Animal Responder to Resistant to
AG (present manuscript) Mice, ﬁsh Valproate, diazepam Levetiracetam, phenytoin, topiramate1
PTZ [15,77,78] Mice, ﬁsh Phenobarbital, valproate, diazepam, ethosuximide, gabapentin2,
levetiracetam3
Phenytoin, carbamazepine, topiramate, lamotrigine
Bicuculline [78,79] Mice Diazepam, ethosuximide, levetiracetam, phenobarbital Gabapentin, lamotrigine, phenytoin, tiagabine, valproate, topiramate
Picrotoxin [78,80] Mice Diazepam, carbamazepine, ethosuximide, phenobarbital,
tiagabine, valproate
Levetiracetam, gabapentin, lamotrigine, topiramate
1 Topiramate showed partial protection in the zebraﬁsh AG model but not in mice.
2 Gabapentin showed activity in mice but not in the zebraﬁsh PTZ test.
3 Levetiracetam decreased the number of SWDs induced by PTZ.
62 K. Leclercq et al. / Epilepsy & Behavior 45 (2015) 53–63high-throughput screening of novel lead compounds in the develop-
ment of therapeutics against treatment-resistant seizures.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yebeh.2015.03.019.
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